Browsing by Autor "Kenji Hirayama"

Now showing 1 - 5 of 5

21-Hydroxylase gene mutant allele CYP21A2∗15 strongly linked to the resistant HLA haplotype B∗14:02-DRB1∗01:02 in chronic Chagas disease
(Elsevier BV, 2013) Florencia del Puerto; Mihoko Kikuchi; Juan Eiki Nishizawa; Yelin Roca; Cinthia Avila; Alberto Gianella; Javier Lora; Freddy Udalrico Gutierrez Velarde; Kenji Hirayama
Blood transfusion and iatrogenic risks in Mexico city: anti-Trypanosoma cruzi seroprevalence in 43,048 blood donors, evaluation of parasitemia, and electrocardiogram findings in seropositive
(Instituto Oswaldo Cruz, Ministério da Saúde, 2005) Nidia Hernández-Becerril; Ana María Mejía‐Jaramillo; Martha A. Ballinas‐Verdugo; Verónica Garza-Murillo; Elsa Manilla-Toquero; Ruth López; S Trevethan; Manuel Cárdenas; Pedro A. Reyes; Kenji Hirayama
Iatrogenous transmission of Trypanosoma cruzi by blood transfusion was suggested as a potential risk by Pellegrino (1949). Seropositive blood donors in Mexico were first reported in 1978, however, limited information is available due to small sampling, the use of heterogeneous serologic assays, and geographically limited studies. A wide survey carried out in 18 out of the 32 states of Mexico, showed a national mean of 1.6% seropositive among 64,969 donors, ranging from 0.2 to 2.8%. In the present study, we have screened 43,048 voluntary blood donors in a period of five years at the Instituto Nacional de Cardiología I. Chávez, a concentration hospital located in Mexico city which serves mainly the metropolitan area and accepts from all over the country. Standardized ELISA and IIF were used to identify seropositive individuals in addition to hemoculture, PCR and standard 12 lead ECG tests that were applied to a group of seropositive patients (29/161). The result showed a seropositivity of 0.37% (161/43,048). From the group of seropositive individuals 40% (12/29) were potential carriers of T. cruzi at the donation time and 5/29 had subclinical ECG abnormalities. Parasitological tests performed in 70 erythrocyte and platelet fractions from seropositive units (70/161) showed negative results. Our findings strongly support T. cruzi screening in the transfusion medicine practice and identify subclinical heart disease among seropositive blood donors.
Follow up study during and after two month regimen of Benznidazole in pediatric chronic Chagas patients in Bolivia
(Japanese Pharmacological Society, 2018) Clara Vásquez Velásquez; Emilio E. Espínola; Zunilda Sánchez; Kota Mochizuki; Jimmy Revollo; Angelica Guzman; Benjamín Quiroga; Juan Eiki Nishizawa; Graciela Russomando; Kenji Hirayama
Introduction: Chagas disease is a parasitic infection endemic in Latin America caused by Trypanosoma cruzi. In Bolivia, vector control activity by the National Program for Chagas has greatly decreased the number of natural infections since 2006. The program began a treatment regimen of Benznidazole (BNZ) (5mg/kg/day) for 2 months in seropositive children aged 4-15 years living in certified vector controlled areas.
Knowledge, behaviour and attitudes towards Chagas disease among the Bolivian migrant population living in Japan: a cross-sectional study
(BMJ, 2020) Inés María Iglesias Rodríguez; Shusaku Mizukami; Đào Huy Mạnh; Thuan Minh Tieu; Hugo Alberto Justiniano; Sachio Miura; George Ito; Nguyen Tien Huy; Chris Smith; Kenji Hirayama
EA with an integrative approach is useful to increase the knowledge of CD within the Bolivian migrant population living in Japan. The activity brings the possibility to explore not only the level of knowledge but also to reveal experiences and to understand the needs of the people at risk. Considering them as actors towards healthcare solutions could lead to better outcomes for the success of future policies and interventions aimed to decrease the global burden.
Proteomic profile of circulating immune complexes in chronic Chagas disease
(Wiley, 2016) Kaname Ohyama; Nguyen Tien Huy; Hiroki Yoshimi; Naoya Kishikawa; Juan Eiki Nishizawa; Yelin Roca; R. J. Revollo Guzmán; Freddy Udalrico Gutierrez Velarde; Naotaka Kuroda; Kenji Hirayama
Immune complexes (ICs) are the direct and real-time products of humoral immune responses. The identification of constituent foreign or autoantigens within ICs might bring new insights into the pathology of infectious diseases. We applied immune complexome analysis of plasma to the study of Chagas disease caused by Trypanosoma cruzi. Twenty seropositive plasma samples including cardiac and/or megacolon determinate patients (n = 11) and indeterminate (n = 9) were analysed along with 10 seronegative individuals to characterize the antigens bound to circulating ICs. We identified 39 T. cruzi antigens and 114 human autoantigens specific to patients with Chagas. Among those antigens, two T. cruzi antigens (surface protease GP63, glucose-6-isomerase) and six human autoantigens (CD180 antigen, ceruloplasmin, fibrinogen beta chain, fibrinogen beta chain isoform 2 preprotein, isoform gamma-A of fibrinogen γ-chain, serum paraoxonase) were detected in more than 50% of the patients tested. Human isoform short of complement factor H-related protein 2 and trans-sialidase of T. cruzi were more frequently found in the indeterminate (5/9 for both) compared with in the determinate Chagas (0/11, P = 0·046 for human, 1/11, P = 0·0498 for T. cruzi). The immune complexome could illustrate the difference of immune status between clinical forms of chronic Chagas disease.